Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update
Unicycive Therapeutics reported Q3 2026 financials, with $59M in cash. The FDA accepted its NDA resubmission for oxylanthanum carbonate (OLC), setting a PDUFA date of March 25, 2027. The company expects runway beyond 2027, including potential OLC launch costs.
How this was made

The 30-second read
Why it matters
The FDA acceptance is a material regulatory milestone; the financials show a modest loss but ample cash runway, setting the stage for a potential launch if approved.
Market read
The news provides a fresh regulatory milestone and earnings data for a micro‑cap biotech, offering a basis for short‑term positioning ahead of the PDUFA decision.
What to watch
Potential pre‑approval inspection of the new manufacturing vendor could delay the timeline.
Background
Unicycive Therapeutics is a Nasdaq‑listed biotech focused on kidney disease treatments, reporting its Q3 2026 results and regulatory update.
Ticker impact
The company announced FDA acceptance of its NDA resubmission for oxylanthanum carbonate with a PDUFA target date of March 25, 2027 and released its Q3 2026 financial results.
potential modest upside as investors price in the chance of approval, but limited upside until FDA decision.
Regulatory progress is a key catalyst for biotech stocks; the cash position supports continued development, but no immediate revenue.
Market effects
Positive signal for the kidney‑disease therapeutic sector as FDA acceptance may encourage peer pipelines.
Limited to US biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech community.
Counterpoint
The NDA acceptance may not translate into approval; investors could remain cautious given the pending review.
Key entities
- CompanyUnicycive Therapeutics, Inc.
Nasdaq‑listed biotech developing oxylanthanum carbonate for hyperphosphatemia.
- RegulatorFDA
U.S. Food and Drug Administration, accepted the NDA resubmission.

